ReviewCancer science2006
Personalized peptide vaccines: a new therapeutic modality for cancer.
Review in Cancer science, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 84 citations in OpenAlex.
- Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.Journal of immunology research · 2016Trial
- Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.Cancer science · 2015Trial
- Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer.Cancer science · 2012Trial
- Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.Cancer science · 2007Trial
- Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.Vaccines · 2024Review
- Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.Cancer science · 2018Article
- Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design.PloS one · 2018Article
- Personalized peptide vaccines and their relation to other therapies in urological cancer.Nature reviews. Urology · 2017Review
- Immunotherapeutic Approaches to Biliary Cancer.Current treatment options in oncology · 2017Review
- Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma.PloS one · 2017Article
- Immunotherapy of biliary tract cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.World journal of gastrointestinal oncology · 2015Review
- Peptide-Based Treatment: A Promising Cancer Therapy.Journal of immunology research · 2015Review
- Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination.Human vaccines & immunotherapeutics · 2015Article
- Current status of immunotherapy for the treatment of biliary tract cancer.Human vaccines & immunotherapeutics · 2013Review
- Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors.Human vaccines & immunotherapeutics · 2013Article
- Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Next-generation peptide vaccines for advanced cancer.Cancer science · 2013Review
- Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer.Human vaccines & immunotherapeutics · 2012Article
- Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis.Experimental and therapeutic medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic cancer vaccines have enjoyed little success so far, although many clinical trials have been conducted. Therefore, the creation of new protocols capable of inducing an objective response is required. We examined two of these protocols in the present review. The first is a personalized protocol to take into account the immunological diversity of cytotoxic T lymphocyte responses among patients. The second is a combination therapy designed to adapt to the presence of major histocompatibility complex (MHC)-loss cancer cells. The objective response rates of our classical (non-personalized) peptide vaccines were 0%, whereas that of personalized vaccines was 11.1% in the total advanced cancers and > or = 20% in malignant glioma and cervical cancers, respectively. A > or = 50% decrease in serum prostate-specific antigen (PSA) was seen in 8.7% of advanced hormone refractory prostate cancer patients by personalized vaccination alone, whereas such a decrease was seen in 54% of patients when the personalized vaccination was combined with a low dose of estramustine. Based on these experiences, we propose a personalized peptide vaccine combined with chemotherapy as a new treatment modality for cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.